Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).

被引：1

作者：

Sher, Amna Falak ^{[1
]}

Bruce, Justine Yang ^{[2
]}

Gabrail, Nashat Y. ^{[3
]}

Anderson, Ian Churchill ^{[4
]}

Patrikidou, Anna ^{[5
]}

Sanborn, Rachel E. ^{[6
]}

Cho, Jae Yong ^{[7
]}

Lee, Arielle Shebay ^{[8
]}

Lee, Jong-Seok ^{[9
]}

Nott, Louise M. ^{[10
]}

Oh, Do-Youn ^{[11
]}

Oh, Sang Cheul ^{[12
]}

Oh, Sung Yong ^{[13
]}

Wang Yinghui ^{[14
]}

Wang Zejing ^{[14
]}

Guthrie, Troy H. ^{[15
]}

机构：

[1] Stony Brook Univ Hosp, Stony Brook, NY USA

[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[3] Gabrail Canc Ctr Res LLC, Canton, OH USA

[4] St Joseph Heritage Healthcare, Santa Rosa, CA USA

[5] Sarah Cannon Res Inst, London, England

[6] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA

[7] Yonsei Univ, Gangnam Severance Hosp, Seoul, South Korea

[8] UT Hlth, HOPE Canc Ctr East Texas, Tyler, TX USA

[9] Seoul Natl Univ, Bundang Hosp, Seongnam Si, South Korea

[10] Royal Hobart Hosp, Hobart, Tas, Australia

[11] Seoul Natl Univ Hosp, Seoul, South Korea

[12] Korea Univ, Guro Hosp, Seoul, South Korea

[13] Dong A Univ Hosp, Busan, South Korea

[14] Seattle Genet Inc, Bothell, WA USA

[15] 21st Century Oncol, Jacksonville, FL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.TPS185

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS185

引用

页数：2

共 50 条

[21] An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer
Bodine P. S. I. Belderbos
Ronald de Wit
Caly Chien
Anna Mitselos
Peter Hellemans
James Jiao
Margaret K. Yu
Gerhardt Attard
Iurie Bulat
W. Jeffrey Edenfield
Fred Saad
Cancer Chemotherapy and Pharmacology, 2018, 82 : 457 - 468
[22] An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
Tsuchiya, Tomohiro
Imanaka, Keiichiro
Iwaki, Yuki
Oyama, Ryo
Hashine, Katsuyoshi
Yamaguchi, Akito
Uemura, Hiroji
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (12) : 1596 - 1604
[23] An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
Tomohiro Tsuchiya
Keiichiro Imanaka
Yuki Iwaki
Ryo Oyama
Katsuyoshi Hashine
Akito Yamaguchi
Hiroji Uemura
International Journal of Clinical Oncology, 2019, 24 : 1596 - 1604
[24] A PHASE 2 OPEN-LABEL TRIAL OF GTX-758 IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER, FINAL ANALYSIS OF THE PRIMARY ENDPOINT
Aronson, William
Yu, Evan
Hancock, Michael
Babicz, Tamas
Tutrone, Ronald
Ng, Christopher
Belkoff, Laurence
Papai, Zsuzsanna
Geczi, Lajos
Getzenberg, Robert
JOURNAL OF UROLOGY, 2016, 195 (04): : E761 - E762
[25] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Alejo Rodriguez-Vida
Pablo Maroto
Albert Font
Cristina Martin
Begoña Mellado
Alex Corbera
Mayra Orrillo
Oscar Reig
Rosa Querol
Alejandro Rios-Hoyo
Laia Cano
Judith Alonso
Gemma Martinez
Susana Galtes
Alvaro Taus
Maria Martinez-Garcia
Nuria Juanpere
Oscar Juan
Joaquim Bellmunt
British Journal of Cancer, 2023, 128 : 21 - 29
[26] An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer
Belderbos, Bodine P. S. I.
de Wit, Ronald
Chien, Caly
Mitselos, Anna
Hellemans, Peter
Jiao, James
Yu, Margaret K.
Attard, Gerhardt
Bulat, Iurie
Edenfield, W. Jeffrey
Saad, Fred
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (03) : 457 - 468
[27] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Rodriguez-Vida, Alejo
Maroto, Pablo
Font, Albert
Martin, Cristina
Mellado, Begona
Corbera, Alex
Orrillo, Mayra
Reig, Oscar
Querol, Rosa
Rios-Hoyo, Alejandro
Cano, Laia
Alonso, Judith
Martinez, Gemma
Galtes, Susana
Taus, Alvaro
Martinez-Garcia, Maria
Juanpere, Nuria
Juan, Oscar
Bellmunt, Joaquim
BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 21 - 29
[28] Utidelone for heavily pretreated metastatic castration-resistant prostate cancer after failing docetaxel treatment: An open-label, single-arm, phase II trial
Chen, Meiting
An, Xin
Xue, Cong
Li, Haifeng
Yang, Wei
Huang, Riqing
Peng, Jing
Tang, Li
Wang, Jun
Li, Yonghong
Shi, Yanxia
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[29] A phase II, open-label, multi-arm study of TAS-115 for castration-resistant prostate cancer patients with bone metastases.
Uemura, Hiroji
Matsubara, Nobuaki
Uemura, Hirotsugu
Nagamori, Satoshi
Suzuki, Hiroyoshi
Kimura, Go
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[30] A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases
Matsubara, Nobuaki
Uemura, Hirotsugu
Nagamori, Satoshi
Suzuki, Hiroyoshi
Uemura, Hiroji
Kimura, Go
CLINICAL GENITOURINARY CANCER, 2021, 19 (06) : 491 - 500

← 1 2 3 4 5 →